| Primary |
| Atrial Fibrillation |
52.6% |
| Drug Use For Unknown Indication |
15.1% |
| Product Used For Unknown Indication |
9.4% |
| Hypertension |
6.0% |
| Atrial Flutter |
3.0% |
| Arrhythmia |
1.4% |
| Blood Pressure |
1.4% |
| Hypothyroidism |
1.3% |
| Anticoagulant Therapy |
1.3% |
| Anxiety |
1.2% |
| Coronary Artery Disease |
1.1% |
| Thrombosis Prophylaxis |
1.1% |
| Diabetes Mellitus |
1.0% |
| Pain |
0.8% |
| Prophylaxis |
0.7% |
| Asthma |
0.6% |
| Cardiac Disorder |
0.5% |
| Chronic Obstructive Pulmonary Disease |
0.5% |
| Osteoporosis |
0.5% |
| Cardioversion |
0.5% |
|
| Atrial Fibrillation |
21.8% |
| International Normalised Ratio Increased |
6.3% |
| Cardiac Failure |
6.3% |
| Ventricular Tachycardia |
5.9% |
| Blood Creatinine Increased |
5.4% |
| Dyspnoea |
5.4% |
| Weight Increased |
5.4% |
| Renal Failure |
5.3% |
| Death |
4.4% |
| Nausea |
4.1% |
| Renal Failure Acute |
3.9% |
| Off Label Use |
3.4% |
| Cardiac Failure Congestive |
3.2% |
| Torsade De Pointes |
3.2% |
| Oedema Peripheral |
3.0% |
| Underdose |
2.8% |
| Palpitations |
2.7% |
| Hyperthyroidism |
2.6% |
| Condition Aggravated |
2.5% |
| Drug Ineffective |
2.5% |
|
| Secondary |
| Atrial Fibrillation |
43.5% |
| Atrial Flutter |
15.2% |
| Anxiety |
11.1% |
| Drug Use For Unknown Indication |
7.2% |
| Product Used For Unknown Indication |
5.0% |
| Hypertension |
4.1% |
| Blood Pressure |
1.5% |
| Arrhythmia |
1.2% |
| Cardioversion |
1.2% |
| Anticoagulant Therapy |
1.2% |
| Hypothyroidism |
1.1% |
| Pain |
1.1% |
| Ventricular Arrhythmia |
1.0% |
| Prophylaxis |
0.9% |
| Chronic Obstructive Pulmonary Disease |
0.9% |
| Blood Cholesterol Increased |
0.8% |
| Tachyarrhythmia |
0.8% |
| Glaucoma |
0.7% |
| Cerebrovascular Accident Prophylaxis |
0.7% |
| Thrombosis Prophylaxis |
0.7% |
|
| Atrial Fibrillation |
12.2% |
| Weight Increased |
7.9% |
| Underdose |
6.9% |
| Wheezing |
6.5% |
| International Normalised Ratio Increased |
6.2% |
| Off Label Use |
5.7% |
| Tachycardia |
5.5% |
| Visual Impairment |
4.7% |
| Nausea |
4.5% |
| Tension Headache |
4.5% |
| Heart Rate Decreased |
4.0% |
| Depression |
3.7% |
| Diarrhoea |
3.7% |
| Hypotension |
3.7% |
| Dyspnoea |
3.5% |
| Fatigue |
3.5% |
| Incorrect Dose Administered |
3.5% |
| Weight Decreased |
3.5% |
| Rash Erythematous |
3.2% |
| Vomiting |
3.2% |
|
| Concomitant |
| Atrial Fibrillation |
34.7% |
| Product Used For Unknown Indication |
13.0% |
| Hypertension |
11.6% |
| Blood Cholesterol Increased |
5.7% |
| Cardiac Disorder |
4.6% |
| Prophylaxis |
3.4% |
| Anticoagulant Therapy |
2.9% |
| Cerebrovascular Accident Prophylaxis |
2.8% |
| Supplementation Therapy |
2.5% |
| Gastrooesophageal Reflux Disease |
2.4% |
| Diabetes Mellitus |
2.3% |
| Hypothyroidism |
2.2% |
| Chronic Obstructive Pulmonary Disease |
2.1% |
| Arrhythmia |
1.8% |
| Anxiety |
1.6% |
| Depression |
1.4% |
| Osteoporosis |
1.4% |
| Rheumatoid Arthritis |
1.4% |
| Asthma |
1.2% |
| Thyroid Disorder |
1.1% |
|
| Gastrointestinal Haemorrhage |
15.8% |
| Atrial Fibrillation |
6.9% |
| Rectal Haemorrhage |
6.5% |
| Diarrhoea |
5.4% |
| Dyspnoea |
5.4% |
| Vomiting |
5.0% |
| Nausea |
4.6% |
| Upper Gastrointestinal Haemorrhage |
4.6% |
| Weight Increased |
4.6% |
| Alopecia |
4.2% |
| Dizziness |
4.2% |
| Haematochezia |
4.2% |
| Weight Decreased |
4.2% |
| Dyspepsia |
3.8% |
| Abdominal Discomfort |
3.5% |
| Arthralgia |
3.5% |
| Fatigue |
3.5% |
| Rash |
3.5% |
| Subdural Haematoma |
3.5% |
| Blood Urine Present |
3.1% |
|
| Interacting |
| Atrial Fibrillation |
29.9% |
| Hypertension |
15.6% |
| Product Used For Unknown Indication |
15.6% |
| Drug Use For Unknown Indication |
12.9% |
| Cerebrovascular Accident Prophylaxis |
4.8% |
| Atrial Flutter |
2.7% |
| Hyperlipidaemia |
2.7% |
| Ischaemic Heart Disease Prophylaxis |
2.7% |
| Urinary Tract Infection |
2.0% |
| Cardiac Failure |
1.4% |
| Gastritis Erosive |
1.4% |
| Glaucoma |
1.4% |
| Hyperthyroidism |
1.4% |
| Tachyarrhythmia |
1.4% |
| Anticoagulant Therapy |
0.7% |
| Arrhythmia |
0.7% |
| Convulsion |
0.7% |
| Coronary Artery Disease |
0.7% |
| Deep Vein Thrombosis |
0.7% |
| Gastritis |
0.7% |
|
| Drug Interaction |
20.0% |
| International Normalised Ratio Increased |
12.5% |
| Torsade De Pointes |
12.5% |
| Cytolytic Hepatitis |
5.0% |
| Exercise Tolerance Decreased |
5.0% |
| Haemorrhage |
5.0% |
| Syncope |
5.0% |
| Tricuspid Valve Incompetence |
5.0% |
| Cardiogenic Shock |
2.5% |
| Decreased Appetite |
2.5% |
| Diarrhoea |
2.5% |
| Dizziness |
2.5% |
| Heart Rate Increased |
2.5% |
| Hepatocellular Injury |
2.5% |
| Long Qt Syndrome |
2.5% |
| Mixed Liver Injury |
2.5% |
| Personality Change |
2.5% |
| Rectal Haemorrhage |
2.5% |
| Renal Failure |
2.5% |
| Septic Shock |
2.5% |
|
